{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:42Z","timestamp":1790007342431,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bone.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T23:08:45Z","timestamp":1560467325000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Osteoblast-specific expression of Panx3 is dispensable for postnatal bone remodeling"],"prefix":"10.1016","volume":"127","author":[{"given":"Timur A.","family":"Yorgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2019.06.008_bb0005","article-title":"The biology of normal bone remodelling","volume":"26","author":"Katsimbri","year":"2017","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.bone.2019.06.008_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","article-title":"Osteoblast and osteocyte: games without frontiers","volume":"561","author":"Capulli","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"5484","key":"10.1016\/j.bone.2019.06.008_bb0015","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"issue":"10169","key":"10.1016\/j.bone.2019.06.008_bb0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bone.2019.06.008_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"ptimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.bone.2019.06.008_bb0035","first-page":"92","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu","year":"2018","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.bone.2019.06.008_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gene.2013.04.069","article-title":"SSkeletal dysplasias with increased bone density: evolution of molecular pathogenesis in the last century","volume":"528","author":"Aggarwal","year":"2013","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bone.2019.06.008_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bone.2019.06.008_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1759720X17726744","article-title":"Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential","volume":"9","author":"McClung","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"1","key":"10.1016\/j.bone.2019.06.008_bb0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jbmr.3283","article-title":"High bone turnover in mice carrying a pathogenic Notch2 mutation causing Hajdu-Cheney syndrome","volume":"33","author":"Vollersen","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2019.06.008_bb0065","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.4049\/jimmunol.1402392","article-title":"harpin controls osteogenic differentiation of mesenchymal bone marrow cells","volume":"195","author":"Jeschke","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.bone.2019.06.008_bb0070","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4049\/jimmunol.181.2.1232","article-title":"Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo","volume":"181","author":"Chang","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bone.2019.06.008_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bone.2019.06.008_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell Metab."},{"issue":"466","key":"10.1016\/j.bone.2019.06.008_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7137","article-title":"Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand","volume":"10","author":"Luther","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bone.2019.06.008_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41413-017-0006-3","article-title":"Lrp1 in osteoblasts controls osteoclast activity and protects against osteoporosis by limiting PDGF-RANKL signaling","volume":"6","author":"Bartelt","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.bone.2019.06.008_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bone.2016.04.012","article-title":"Osteoblast-specific Notch2 inactivation causes increased trabecular bone mass at specific sites of the appendicular skeleton","volume":"87","author":"Yorgan","year":"2016","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2019.06.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050301","article-title":"Pharmacological estrogen administration causes a FSH-independent osteo-anabolic effect requiring ER alpha in osteoblasts","volume":"7","author":"Seitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2019.06.008_bb0105","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1038\/ncomms6215","article-title":"Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts","volume":"5","author":"Keller","year":"2014","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bone.2019.06.008_bb0110","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/jbmr.2461","article-title":"The anti-osteoanabolic function of sclerostin is blunted in mice carrying a high bone mass mutation of Lrp5","volume":"30","author":"Yorgan","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.06.008_bb0115","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.06.008_bb0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1083\/jcb.201207142","article-title":"Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin","volume":"200","author":"Albers","year":"2013","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bone.2019.06.008_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2019.06.008_bb0130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1172\/JCI119276","article-title":"Pex\/PEX tissue distribution and evidence for a deletion in the 3\u2032 region of the Pex gene in X-linked hypophosphatemic mice","volume":"99","author":"Beck","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bone.2019.06.008_bb0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00774-010-0221-0","article-title":"Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice","volume":"29","author":"Hanagata","year":"2011","journal-title":"J. Bone Miner. Metab."},{"issue":"11","key":"10.1016\/j.bone.2019.06.008_bb0140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/mend.11.11.0008","article-title":"Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo","volume":"11","author":"Sims","year":"1997","journal-title":"Mol. Endocrinol."},{"issue":"11","key":"10.1016\/j.bone.2019.06.008_bb0145","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1096\/fj.15-273722","article-title":"Pannexin 3 is required for normal progression of skeletal development in vertebrates","volume":"29","author":"Oh","year":"2015","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0150","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1242\/jcs.176883","article-title":"Pannexin 3 and connexin 43 modulate skeletal development through their distinct functions and expression patterns","volume":"129","author":"Ishikawa","year":"2016","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.bone.2019.06.008_bb0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bone.2019.06.008_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcdb.2015.12.017","article-title":"Connexins in the skeleton","volume":"50","author":"Stains","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.bone.2019.06.008_bb0165","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cell.2015.05.029","article-title":"Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation","volume":"161","author":"Wei","year":"2015","journal-title":"Cell"},{"issue":"7381","key":"10.1016\/j.bone.2019.06.008_bb0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature10763","article-title":"The contribution of bone to whole-organism physiology","volume":"481","author":"Karsenty","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bone.2019.06.008_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","author":"Nakashima","year":"2002","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bone.2019.06.008_bb0180","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0185","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2019.06.008_bb0190","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2019.06.008_bb0195","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.17219\/acem\/68739","article-title":"Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders","volume":"26","author":"Pietrzyk","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.bone.2019.06.008_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bone.2016.11.024","article-title":"Sclerostin expression and functions beyond the osteocyte","volume":"96","author":"Weivoda","year":"2017","journal-title":"Bone"},{"issue":"24","key":"10.1016\/j.bone.2019.06.008_bb0205","doi-asserted-by":"crossref","first-page":"18948","DOI":"10.1074\/jbc.M110.127027","article-title":"Pannexin 3 regulates intracellular ATP\/cAMP levels and promotes chondrocyte differentiation","volume":"285","author":"Iwamoto","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bone.2019.06.008_bb0210","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1083\/jcb.201101050","article-title":"Pannexin 3 functions as an ER Ca(2+) channel, hemichannel, and gap junction to promote osteoblast differentiation","volume":"193","author":"Ishikawa","year":"2011","journal-title":"J. Cell Biol."},{"issue":"8","key":"10.1016\/j.bone.2019.06.008_bb0215","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00109-015-1311-1","article-title":"Deletion of Panx3 prevents the development of surgically induced osteoarthritis","volume":"93","author":"Moon","year":"2015","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0220","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/joa.12437","article-title":"Global deletion of Panx3 produces multiple phenotypic effects in mouse humeri and femora","volume":"228","author":"Caskenette","year":"2016","journal-title":"J. Anat."},{"issue":"12","key":"10.1016\/j.bone.2019.06.008_bb0225","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/jbmr.509","article-title":"Pannexin 3 is a novel target for Runx2, expressed by osteoblasts and mature growth plate chondrocytes","volume":"26","author":"Bond","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000338758","article-title":"Expression of pannexin isoforms in the systemic murine arterial network","volume":"49","author":"Lohman","year":"2012","journal-title":"J. Vasc. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.06.008_bb0235","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/jid.2014.86","article-title":"Panx1 regulates cellular properties of keratinocytes and dermal fibroblasts in skin development and wound healing","volume":"134","author":"Penuela","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bone.2019.06.008_bb0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fnmol.2018.00135","article-title":"A potential compensatory role of Panx3 in the VNO of a Panx1 knock out mouse model","volume":"11","author":"Whyte-Fagundes","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.bone.2019.06.008_bb0245","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00109-019-01779-9","article-title":"Double deletion of Panx1 and Panx3 affects skin and bone but not hearing","volume":"97","author":"Abitbol","year":"2019","journal-title":"J. Mol. Med. (Berl.)"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:45:18Z","timestamp":1757612718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219302406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":49,"alternative-id":["S8756328219302406"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.008","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoblast-specific expression of Panx3 is dispensable for postnatal bone remodeling","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}